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Axonal elongation and guidance are controlled by extracellular factors such as the neurotrophins. Indeed, nerve growth
factor (NGF) seems to promote axon growth through binding to its p75NTR receptor and inactivating RhoA. Furthermore,
the local inhibition of glycogen synthase kinase (GSK)-3 by NGF also favors microtubule polymerization and axon
extension. Inactivation of GSK-3 may be due to the NGF/TrkA-mediated activation of phosphatidylinositol-3 kinase
(PI-3 kinase), which increases the levels of phosphatydilinositol 3-phosphate [PI(3)P]. However, we show here that NGF
may inactivate GSK-3 through an alternative mechanism. In cultured hippocampal neurons, the capacity of NGF to
promote axon elongation is mostly mediated by p75NTR, and the activation of this pathway leads to the inactivation of
GSK-3. However, the signaling pathway triggered by NGF/p75NTR acts through casein kinase II (CK2). NGF/p75NTR-
activated CK2 phosphorylates the phosphatase and tensin homologue deleted on chromosome 10 (PTEN), thus rendering
this phosphatase inactive. Like activation of the PI-3 kinase, PTEN inactivation allows PI(3)P levels to increase, thus
favoring GSK-3 inactivation and axon outgrowth. This newly disclosed mechanism may help to extend the repertoire of
pharmacological agents that activate CK2 or that inhibit PTEN to stimulate axon regeneration after trauma or disease.
INTRODUCTION
Neurons are highly polarized cells that display a very varied
structural and functional specialization. At the cellular level,
neuronal polarity is principally based on the fact that axons
send signals, whereas dendrites receive them. Indeed, this is
essential to ensure the flow of information within the nervous
system and between the nervous system and other tissues.
Although all neurites initially have the potential to become an
axon, only when one of the multiple neurites begins to grow
rapidly does specialization commence. This fast-growing neu-
rite will become the future axon, the other neurites will con-
tinue to develop as dendrites (Bradke and Dotti, 2000). Both the
maintenance of axon identity and the promotion of axonal
growth and guidance are controlled by extracellular cues. Such
cues may be derived from either diffusible factors or from
membrane-associated ligands. Thus, netrins, slit, semaphorins,
ephrins, Wnts, sonic hedgehog, bone morphogenetic proteins,
insulin and insulin-like growth factor (IGF)-I and neurotro-
phins all either promote or impair axonal outgrowth.
Some of the extracellular factors that promote axonal
growth, such as insulin and IGF-I, Wnts, and neurotrophins,
do so by inhibiting glycogen synthase kinase (GSK)-3. Lo-
cal inactivation of GSK-3 in an immature neurite suffices to
specify an axon (Yoshimura et al., 2005). Furthermore, inac-
tivation of GSK-3 causes dephosphorylation of certain mi-
crotubule binding proteins, such as collapsin response me-
diator protein 2 and adenomatous polyposis coli. In their
nonphosphorylated state, these proteins bind to - and -tu-
bulin with higher affinity, thereby favoring microtubule po-
lymerization and axon extension (Yoshimura et al., 2005;
Zhou et al., 2004; Zhou and Snider, 2005). One means to
inactivate GSK-3 is through Ser9 phosphorylation by Akt/
PKB (Cross et al., 1995). This kinase itself is activated upon
its phosphorylation by the phosphoinositide-dependent ki-
nase. Indeed, the whole process is dependent on the levels of
the phosphatydilinositol 3-phosphate [PI(3)P] pool that is
generated by activated phosphatidylinositol 3-kinase (PI-3
kinase) (Alessi et al., 1996; Stokoe et al., 1997; Stephens et al.,
1998). It is therefore highly relevant that the Trk receptors
activated by neurotrophins can themselves in turn activate
PI-3 kinase (Segal, 2003; Vaillant et al., 1999; Zhou et al.,
2004). Hence, it seems likely that neurotrophin/Trk acti-
vated PI-3 kinase is an upstream element in the inhibition of
GSK-3, which would constitute a molecular correlate for
NGF-promoted axonal growth (Zhou et al., 2004).
In this communication, we show that NGF promotes ax-
onal outgrowth in cultured hippocampal neurons by inhib-
iting GSK-3 after the activation of Akt/PKB via its p75NTR
receptor. The interaction of NGF with p75NTR activates ca-
sein kinase II (CK2), which in turn inactivates the phospha-
tase and tensin homolog deleted on chromosome10 (PTEN),
a phosphatase that antagonizes the PI-3 kinase pathway
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(Maehama and Dixon, 1998; Maehama and Dixon, 1999;
Stiles et al., 2004). In this way, PI(3)P levels increase favoring
the inhibition of GSK-.
MATERIALS AND METHODS
Transfection Vectors
The HA-GSK-3 S9A/pcDNA3.1 vector that contains a constitutively active
form of GSK-3 was generously provided by Dr. J. R. Woodgett (Ontario
Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada). The
pEGFP-N1 vector to express enhanced green fluorescent protein (EGFP) was
obtained from Clontech (Palo Alto, CA).
Antibodies
The primary antibodies used in this study were anti-p75NTR rabbit polyclonal
antiserum (Advances Targeting Systems, San Diego, CA) used at a dilution of
Figure 1. NGF induced axonal elongation is mediated via p75NTR
in hippocampal neurons. Cells were plated onto glass coverslips at
a density of 150 neurons/mm2. After 2 DIV, NGF or NGF plus the
p75-antibody or NGF plus 1% rabbit neutral serum was added to
the cells and incubated for a further 16 h. In parallel experiments,
the Trk inhibitor K252a was added to the cells in the absence or
presence of NGF and incubated for a further 16 h. Digital fluores-
cence images of phosphorylated neurofilament immunostaining by
SMI31 mAb in control cultures (A), 100 ng/ml NGF (B), 100 ng/ml
NGF plus p75-antibody antiserum, diluted 1:100 (C); or 200 nM
K252a (D). The means, SE, and number of the neurons observed (in
brackets) for each treatment are shown (E and F). Note that NGF
induced axon elongation and the application of the anti-p75NTR
blocking antibody prevented such an effect, whereas the application
of the neutral rabbit serum did not (E). In contrast, K252a did not
prevent the axon growth promoted by NGF, although, by itself,
decreased axon length (F). Here and in the following figures, the
levels of significance (asterisks) were determined for the data sets
connected by horizontal lines using an unpaired t test. *p  0.05,
**p  0.01, and ***p  0.001.
Figure 2. GSK-3 activation reduced axon length and prevented
NGF-induced axonal growth. (A and B) Control cultures were trans-
fected with EGFP, whereas in parallel cultures, neurons were co-
transfected with vectors expressing EGFP and GSK-3 S9A, a con-
stitutively active form of GSK-3. Some cells were treated with
NGF, and after 16 h, the cells were immunostained with the axon
marker SMI31 and with anti-EGFP to detect the cotransfected pro-
teins (arrows). Axon length was determined in EGFP-transfected
and in EGFP plus GSK-3 S9A-cotransfected in the absence or in the
presence of NGF (B). Note that NGF was incapable of increasing
axon length in cells transfected with the constitutively active form of
GSK-3. (C) Cultures of hippocampal neurons were treated at 2 DIV
with NGF, LPA (an activator of GSK-3), or both during 16 h and
then fixed and stained with the axon marker SMI31. Note that the
axon growth in cells in which GSK-3 was stimulated was similar to
that in those transfected with a constitutive enzyme.
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1:100; anti-phosphorylated neurofilament monoclonal antibody (mAb) SMI31
(Sternberger Monoclonals, Lutherville, MA) used at a dilution of 1:500; anti-
hemagglutinin (HA) mAb 12CA5 (Roche Diagnostics, Indianapolis, IN) used
at a dilution of 1:500; rabbit anti-green fluorescent protein (GFP) antiserum
(Molecular Probes Europe, Leiden, Holland) used at a dilution of 1:500,
anti-GSK-3 mAb (BD Transduction Laboratories, Lexington, KY) used at a
dilution of 1:10,000; rabbit anti-phospho-GSK-3/ Ser21/9 (Cell Signaling
Technology, Beverly, MA) antiserum used at a dilution of 1:2500; rabbit
anti-phospho-Akt Ser473 antiserum (Cell Signaling Technology) used at a
dilution of 1:2500; a rabbit anti-Akt antiserum used at a dilution of 1:5000
dilution (Cell Signaling Technology); and a rabbit anti-phospho-PTEN Ser380
antiserum (Cell Signaling Technology) used at a dilution of 1:5000. The
anti-unique -tubulin mAb TUJ1 was used at a dilution of 1:2000 (Berkeley
Antibody, Richmond, CA). All the secondary antibodies were obtained from
Jackson ImmunoResearch Laboratories (West Grove, PA).
Chemicals
NGF was purified from mouse salivary glands and was a gift from Hermann
Rohrer (Max Planck Institute for Brain Research, Frankfurt, Germany). 1-Oleyl-9-
(cis)-2-lyso-sn-glycero-3 phosphate (LPA) was from Sigma-Aldrich (St. Louis,
MO). The K252a inhibitor of membrane tyrosine kinases, the specific CK2
inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT)
(Pagano et al., 2004), and the PTEN inhibitor dipotassium bisperoxo(picolinato)
oxovanadate (V) [bpV(pic)] (Schmid et al., 2004) were all purchased from Cal-
biochem (San Diego, CA).
Hippocampal Neuronal Cultures, Neuron Transfection,
and Incubation Conditions
The hippocampus was dissected out from embryonic day 17 mouse embryos
and dissociated to single cells after digestion with trypsin (Worthington
Biochemicals, Freehold, NJ) and DNase I (Sigma-Aldrich) (Goslin and Banker,
1989). To determine axon length, neurons were plated on glass coverslips
coated with poly-l-lysine (Sigma-Aldrich) at a density of 150–300 neurons/
mm2, and they were cultured in Neurobasal A supplemented with B-27 and
GlutaMAX I (Invitrogen, Crewe, United Kingdom). After 1–2 days in vitro
(DIV), cultured neurons were transfected using the Effectene transfection
reagent (QIAGEN, Hilden, Germany) and treated with either 100 ng/ml NGF,
anti-p75-antibody (1:100), or 10 M LPA for 16 h. The neurons were then
processed for immunostaining.
In other experiments, neurons were plated on coated plastic dishes (see
above) and after 7 DIV, the medium was replaced by fresh medium devoid of
B27 supplement for 2 h before the cells were exposed to either 100 ng/ml
NGF, anti-p75-antibody (1:100), 200 nM K252a, 200 nM bpV(pic), or 10 M
DMAT for 1 h. The cells were then lysed in lysis buffer (20 mM HEPES, pH
7.5, 100 mM NaCl, 100 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 1% Triton
X-100, 100 nM okadaic acid, and an anti-protease cocktail; Roche Diagnostics,
Mannheim, Germany), and the cells were scraped and recovered from the
culture dish. The suspension was maintained on ice for 10 min and then
centrifuged at 15,000  g for 15 min at 4°C. The supernatant was used for
Western analysis and in kinase assays after estimating the protein content
using the DC&RC method (Bio-Rad, Munich, Germany).
Western Blot Analysis
Equal amounts of protein (10–20 g) were resolved by SDS-PAGE on 10%
acrylamide gels after diluting the samples in loading buffer and heating them
to 100°C for 3 min. After electrophoresis, the proteins were transferred to
nitrocellulose membranes that were incubated in blocking buffer (Tris-buff-
ered saline with 0.1% Tween 20 [Sigma-Aldrich], and 5% nonfat dry milk).
The membranes were subsequently probed with primary antibodies and then
Figure 3. Time course of NGF-induced inactivation of GSK-3. (A)
GSK-3 (  ) activity was determined in cytosolic extracts from 7
DIV cultures of hippocampal neurons treated with 100 ng/ml NGF
for the times reflected in the graph. (B) Western blots analysis of the
same extracts with anti-phospho-GSK-3/ (Ser21/9) (top) and
anti-GSK-3 (bottom) antibodies. Note that the inactivation of
GSK-3 correlates with the levels of Ser9 phosphorylation.
Figure 4. NGF inactivates GSK-3 via p75NTR. (A) GSK-3 activity
was determined in extracts from cultured hippocampal neurons
that were incubated for 1 h in the presence or absence of 100 ng/ml
NGF, 100 ng/ml NGF plus anti-p75NTR blocking antibody (1:100
diluted), or 100 ng/ml NGF plus K252a, a Trk inhibitor. Observe
that the blockage of p75NTR prevented the NGF-induced inhibition
of the kinase, whereas the inhibition of Trk receptors by K252a did
not affect the inhibition of GSK-3 by NGF. (B) Western blot analysis
of the same samples with anti-phospho-GSK-3/ (Ser21/9) (top)
and anti-GSK-3 (bottom) antibodies. The asterisk indicates the
band corresponding to the heavy chain of the anti-p75 antibody.
Note that in the presence of the p75-antibody, NGF did not induce
Ser9 phosphorylation of the enzyme, whereas inhibition of the Trk
receptor by K252a did not change the NGF-induced phosphoryla-
tion pattern. (C) Densitometric quantification of Western blots from
three different experiments.
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incubated with the corresponding peroxidase-conjugated secondary antibodies.
Immunoreactivity was visualized using an enhanced chemiluminescence de-
tection system (GE Healthcare, Little Chalfont, Buckinghamshire, United
Kingdom) and the intensity of the bands was evaluated by densitometric
analysis using Quantity One software (Bio-Rad).
Endogenous GSK-3 and CK2 Activity in Cell Lysates
GSK-3 assays were performed essentially as described previously (Sayas et
al., 1999). Cells were collected and homogenized in lysis buffer and the soluble
fraction was used for the kinase assays. Protein samples (5 g) were incubated
in buffer (25 mM Tris, pH 7.5, 1 mM dithiothreitol, and 10 mM MgCl2)
containing the specific substrate peptide 2B-SP at a final concentration of 0.75
mg/ml (Welsh et al., 1997), and in the presence of [-32P]ATP (50 l final
reaction volume). After 40 min at 30°C, the reaction was stopped by spotting
aliquots onto P81 phosphocellulose paper and the radioactivity was measured
by scintillation counting. The difference between the kinase activity in the
presence or absence of 20 mM LiCl was considered as the measure of GSK-3
protein kinase activity.
CK2 activity was assayed using a casein kinase 2 assay kit (Upstate Bio-
technology, Lake Placid, NY). The specific peptide R3D3SD3 (1 mM) was
added to cleared lysate containing 2.5–5 g of protein in the presence of
[-32P]ATP and a PKA inhibitor cocktail (50 l total reaction volume). After 15
min at 30°C, the reaction was stopped by adding 20 l of 40% trichloroacetic
acid, and the phosphorylated substrate was separated from the residual
[-32P]ATP using P81 phosphocellulose paper. The radioactivity incorporated
into the substrate was quantified by scintillation counting.
Image Acquisition and Morphometric Analysis of
Immunolabeled Hippocampal Neurons
Labeled neurons were observed under a Zeiss Axiophot 2 microscope, using
a plan-neofluor 40 oil objective with a numerical aperture of 1.3 (Carl Zeiss,
Oberkochen, Germany). Images of 20 neurons per coverslip were acquired
digitally (camera DP-10; Olympus, Tokyo, Japan) and imported to the final
figures that were generated using CorelDraw 12 (Corel, Ottawa, Ontario,
Canada). To measure axon length we used the ImageJ public domain software
(developed at the National Institutes of Health, Bethesda, MD). Only neurons
with a defined axon were evaluated, and axons were recognized by SMI31
antibody immunoreactivity.
RESULTS
NGF Induces Axonal Elongation through the Activation of
p75NTR
After 2 DIV, most hippocampal neurons from E17 mouse
embryos are to a large extent polarized (Dotti et al., 1988;
Goslin and Banker, 1989). By this stage, one of their pro-
cesses has acquired axonal identity, usually the longest, and
is recognized by the SMI31 antibody (Pennypacker et al.,
1991) (Figure 1, A–D). In our experimental model, incuba-
tion of 2 DIV neurons with NGF for 16 h increased the length
of axons by 35–80% (Figure 1, A, B, E, and F). Because TrkA
mediates NGF-promoted axon elongation in other model
systems (Kuruvilla et al., 2004; Goold and Gordon-Weeks,
2005), we assessed the role of p75NTR in NGF-promoted axon
elongation in hippocampal neurons. To this end, the neurons
were exposed to an anti-p75NTR antiserum before applying
NGF to the cultures. This antiserum is raised against the ex-
tracellular domain of p75NTR, and it blocks the binding of NGF
to the receptor (Huber and Chao, 1995). Although the antibody
itself did not affect axon growth (our unpublished data), im-
pairing NGF binding to p75NTR largely prevented axonal elon-
gation (Figure 1, C and E). The presence of rabbit nonimmune
serum did not prevent the axonal growth induced by NGF
(Figure 1E). Furthermore, although the presence of K252a, a
known Trk inhibitor, significantly reduced axon length, it
did not prevent the axon growth promoted by NGF (Figure
1, D and F). Therefore, our results indicated that in hip-
pocampal neurons, p75NTR mediates the axon growth pro-
moted by NGF.
Role of GSK-3 in the NGF/p75NTR-induced Axon Growth
Previous studies have shown that p75NTR controls axonal elon-
gation by activating or inactivating the RhoA GTPase, depend-
ing on the ligand that binds to the receptor (Wong et al., 2002;
Yamashita et al., 2002; Yamashita and Tohyama, 2003; Gehler et
al., 2004). However, in view of the evidence that NGF may
promote axon elongation by inhibiting GSK-3, we wanted to
know whether an alternative signaling pathway to promote
axon elongation might be triggered by p75NTR (Zhou et al.,
2004; Jiang et al., 2005; Yoshimura et al., 2005). Therefore, we
examined whether p75NTR might mediate axon elongation by
inhibiting GSK-3 activity after NGF activation.
To determine whether the participation of p75NTR in axon
elongation of hippocampal neurons involves GSK-3, we
transfected a constitutively active form of GSK-3 (GSK-
3S9A) into cultured neurons (Doble and Woodgett, 2003).
These transfected neurons grew shorter axons, and the ap-
plication of NGF did not produce any effect in terms of
axonal growth (Figure 2, A and B). These results suggested
that NGF does indeed induce axonal growth by inactivating
GSK-3. To further assess the role of NGF/p75NTR signaling
in axon elongation, we measured the axonal length of cul-
tured neurons in the presence of NGF and LPA, a known
activator of GSK-3 (Sayas et al., 1999, 2002). LPA alone not
only inhibited axonal growth but also prevented NGF from
promoting axonal growth (Figure 2C), suggesting that this
axon growth stimulated by NGF occurred through the inac-
tivation of the GSK-3. To examine this phenomenon more
closely, we first carried out a time course of kinase activity in
protein extracts of neurons after NGF application. Thus, a
significant inactivation of GSK-3 activity was observed 30
min after treatment NGF (Figure 3A), which was maximal at
60 min. This inactivation of GSK-3 activity was paralleled by
the NGF-induced phosphorylation of GSK-3 at its Ser9
residue, which is known to inhibit this enzyme (Figure 3, A
and B).
To determine through which receptor NGF acts when
influencing axonal growth, GSK-3 activity was measured
directly in the presence of NGF, NGF plus the anti-p75NTR
blocking antibody, and NGF plus the Trk receptor inhibitor
K252a. The decrease of GSK-3 activity induced by NGF was
inhibited by the presence of the anti-p75 blocking antibody
(Figure 4A), whereas K252a did not affect the influence
exerted by NGF on enzyme activity. Furthermore, these
Figure 5. NGF inactivates GSK-3 through a pathway different
from PI-3 kinase activation. (A) GSK-3 activity was determined in
extracts from cultured hippocampal neurons that were incubated
for 1 h in the presence or absence of 100 ng/ml NGF, LY294002, a
known inhibitor of PI-3 kinase, and 100 ng/ml NGF plus LY294002.
Note that in the presence of the PI-3 kinase inhibitor, NGF was still
capable of inhibiting GSK-3, suggesting an alternative pathway for
NGF-induced GSK-3 inhibition. (B) NGF induced axon elongation
is not prevented by inhibition of PI-3 kinase. Note that axon growth
corresponds to the inhibition state of GSK-3.
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changes in GSK-3 activity were paralleled by changes in
Ser9 phosphorylation (Figure 4, B and C). Together, our re-
sults indicate that the activity of NGF in promoting axonal
growth is triggered by the binding of this neurotrophin to
the p75NTR receptor and that this effect is mediated by the
inhibition of GSK-3.
NGF Controls PTEN Activity through p75NTR
Binding of neurotrophins to their specific Trk receptors
strong stimulates both the MAPK and the PI-3 kinase path-
ways (Segal, 2003). Of these, PI-3 kinase has been shown to
be involved in axon morphogenesis and in the inactivation
of GSK-3 (Segal, 2003; Zhou et al., 2004; Zhou and Snider,
2005). In cultured hippocampal neurons, we determined
whether NGF could still inactivate GSK-3 when the PI-3
kinase was specifically inhibited by LY294002. When GSK-3
activity in neurons was measured directly in the presence of
LY294002, NGF was still capable of inhibiting the activity of
the kinase significantly (Figure 5A). These results suggest
that NGF-induced inhibition of GSK-3 was at least partially
independent of PI-3 kinase. We then studied the effects of
NGF on axonal growth in short-term cultures of neurons
treated with LY294002. Thus, as shown in Figure 5B, NGF
induced axon growth under conditions of PI-3 kinase inhi-
Figure 6. The PTEN phosphatase lies in the pathway leading to NGF-induced activation of Akt/PKB and inhibition of GSK-3. Cultures
of hippocampal neurons were treated with either 100 ng/ml NGF, bpV(pic) (a selective inhibitor of PTEN phosphatase), or LY296002 (an
inhibitor of PI-3 kinase) in different combinations, and the cytosolic extracts were then analyzed for Akt, p-Akt (A), and quantified by
densitometry. The same extracts were used to analyze GSK-3 and p-GSK-3 by Western blotting (B), and its densitometric quantification
is shown in B. NGF and bpV(pic) were used in combination, and they did not show additive effects in terms of Akt and GSK-3
phosphorylation (C) and axon elongation (D).
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bition. Together, our results strongly suggest that NGF-
induced axon elongation and GSK-3 inhibition are not de-
pendent on PI-3 kinase activation. Therefore, we considered
whether a phosphatase that acts on PI(3)P might be involved
in the events induced by NGF activation of p75NTR, the
inhibition of which may lead to GSK-3 inactivation and the
subsequent elongation of the axon.
PTEN has been related with both GSK-3 activity and
neuronal polarity (Jiang et al., 2005). To test the involvement
of PTEN as an upstream element in GSK-3 signaling, cul-
tured hippocampal neurons were treated with bpV(pic), which
specifically inhibits PTEN at low concentrations (Schmid et al.,
2004), and the phosphorylation of Akt/PKB (in Ser473) was
determined by Western blotting. The phosphorylation of Akt/
PKB reflects the levels of PI(3)P in the cytoplasm of the cul-
tured neurons. Exposing the cultured neurons to bpV(pic)
increased the phosphorylation of Akt/PKB to levels similar to
those produced by NGF (Figure 6, A and C). As expected,
LY294002 largely depressed the phosphorylation of the kinase,
which was partially restored by applying NGF to the medium.
Thus, the application of a pharmacological inhibitor of PTEN
caused the same effect on Akt/PKB phosphorylation as the
application of NGF, suggesting that this neurotrophin also
inhibits the phosphatase. Indeed, under all experimental con-
ditions the phosphorylation of Akt/PKB was paralleled by that
of GSK-3 (Figure 6, A and B), suggesting that Akt/PKB phos-
phorylates and inhibits GSK-3. Furthermore, these results
indicate that the inhibition of GSK-3 by NGF may at least in
part be due to the inhibition of PTEN by NGF. As shown
above, both NGF and bpV(pic) induce phosphorylation of Akt
and GSK-3. Consistently, bpV(pic), like NGF, induced axon
elongation (Figure 6F). Neither in inducing phosphorylation of
Akt and GSK-3 nor in promoting axon growth had NGF and
the phosphatase inhibitor additive effects (Figure 6, E and F).
We further tested the relationship between NGF signaling
and the activity of the PTEN phosphatase by applying NGF
to cultured hippocampal neurons and assessing the phos-
phorylation of PTEN at Ser 380 (Figure 7A). Phosphoryla-
tion of this residue was observed after 30-min incubation in
the presence of NGF, and it was maintained for at least 2 h.
The increase of PTEN phosphorylation induced by NGF was
mediated through p75NTR because prior addition of the
anti-p75 blocking antibody prevented PTEN phosphoryla-
tion (Figure 7, B and C). As a control, the application of
rabbit nonimmune serum did not prevent PTEN phosphor-
ylation promoted by NGF (Figure 7, B and C). These results
demonstrate the relationship between NGF/p75NTR and
PTEN phosphorylation and in conjunction with the results
described above, strongly suggest that this phosphorylation
has an inhibitory effect on phosphatase activity.
CK2 Mediates NGF-induced Axonal Growth
CK2 phosphorylates PTEN (Torres and Pulido, 2001), and
because NGF and EGF stimulate CK2 activity in PC12 cells
(Kleijn et al., 1998), we determined whether this kinase might
be involved in NGF/p75NTR signaling. To test whether NGF
might affect CK2 in hippocampal neurons, we assessed the
activity of this kinase in cytosolic extracts from cultured
hippocampal neurons previously incubated with either NGF
and/or DMAT (a specific CK2 inhibitor; Pagano et al., 2004).
Direct measurement of CK2 activity clearly showed that this
kinase was activated by exposure to NGF and that this
activation could be prevented by prior application of DMAT
(Figure 8A). Furthermore, the NGF-induced activation of
CK2 was also prevented in the presence of the anti-p75NTR
blocking antibody but not by the presence of rabbit nonim-
mune serum (Figure 8B). Moreover, in our assay CK2 activ-
ity was abolished in the presence of heparin in the kinase
reaction mixture, a known inhibitor of the CK2 (Hathaway et
al., 1980). This served as a positive control for the assay and
ensured that only genuine CK2 activity was measured (con-
trols not shown). Moreover, a correlation between NGF-
induced CK2 activity and NGF-induced axonal outgrowth
was also found. Thus, Figure 8C shows that the inhibition of
CK2 by DMAT counteracted the axonal growth induced by
NGF.
Both phosphorylation of the PTEN phosphatase at Ser380
(presumably inhibitory; see Discussion) and of GSK-3 at
Ser9 (certainly inhibitory) were also assayed in parallel (Fig-
ure 8, D and E). Consistent with previous data, exposure to
NGF augmented the phosphorylation of both enzymes. In
contrast, the phosphorylation of both enzymes diminished
in the presence of the CK2 inhibitor DMAT, both in neurons
grown in the presence or the absence of NGF. Together, our
results reveal a new pathway for NGF/p75NTR that controls
the activity of the PTEN phosphatase through CK2 activa-
tion, this phosphatase lying upstream of GSK-3 in this
signaling cascade.
Figure 7. NGF induces phosphorylation of PTEN phosphatase. (A)
Maximum phosphorylation was achieved 30 min after the applica-
tion of NGF to the cultured hippocampal neurons. (B) Western blot
analysis showing that prior application of the anti-p75 blocking
antibody to cultured neurons prevented NGF-induced phosphory-
lation of PTEN phosphatase, whereas the addition of neutral rabbit
serum did not. Quantitative results are the average of (n) different
experiments, shown in C.
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DISCUSSION
We have shown here that via p75NTR, NGF stimulates
axonal elongation in cultured hippocampal neurons by
inhibiting GSK-3 activity. More importantly, in our ex-
perimental system the NGF/p75NTR induced inhibition of
GSK-3 was not entirely mediated through the activation
of PI-3 kinase but rather by NGF/p75NTR-induced inhibi-
tion of PTEN phosphatase. Thus, it seems most likely that
the inhibition of the PTEN phosphatase increases the levels of
phosphoinositol-3 phosphate to a state necessary to acti-
vate Akt/PKB and therefore to phosphorylate GSK-3.
Our data reveal a new signaling pathway by which NGF/
p75 NTR inhibits GSK-3, thus promoting axon elonga-
tion (Figure 9).
The Role of p75NTR in NGF-promoted Inhibition of
GSK-3 and Axon Elongation
p75NTR has been shown to control axon growth in a variety
of model systems. However, all these studies have pointed
to RhoA as the mediator of NGF/p75NTR signaling. Indeed,
this small GTPase can be both activated or deactivated by
p75NTR, depending on the ligand that is bound to this re-
ceptor, and on the other membrane proteins to which the
neurotrophin receptor may be associated (Wong et al., 2002;
Yamashita et al., 2002; Yamashita and Tohyama, 2003;
(Gehler et al., 2004). By binding to p75NTR, NGF inhibits the
capacity of the receptor to activate RhoA, thus favoring axon
growth (Wong et al., 2002; Yamashita et al., 2002; Yamashita
and Tohyama, 2003). However, neurotrophin signaling may
Figure 8. NGF-activated CK2 participates in NGF/p75NTR signaling, leading to PTEN and GSK-3 phosphorylation and subsequent axonal
growth. (A) CK2 activity was determined from cytosolic extracts obtained from cultured hippocampal neurons. Cultures were incubated for
30 min in the presence or absence of NGF, DMAT (a specific CK2 inhibitor), or NGF plus DMAT. Observe that NGF augmented the kinase
activity, and this increase was prevented by the presence of DMAT, highlighting the specificity of NGF-induced CK2 activity. (B) NGF
activation of CK2 is mediated by p75NTR. Cultured neurons were incubated for 30 min either in the presence or absence of 100 ng/ml NGF
or of NGF plus anti-p75-antibody blocking antibody. Note that there is a significant increase of CK2 activity upon exposure of the cells to
NGF, and this effect is neutralized by the presence of the antibody. Also note that the inclusion of a rabbit neutral serum did not block NGF
activity. (C) Inhibition of CK2 by DMAT prevented NGF-promoted axon elongation. (D) NGF-induced CK2 activation correlates with the
NGF-induced phosphorylation of PTEN and Ser9 phosphorylation of GSK-3. Staining for 3-tubulin was included as a loading control.
Observe that NGF did not increase the Ser9 phosphorylation of GSK-3 when CK2 was inhibited by DMAT. (E) Quantification of the
densitometric signals from D are the average of three independent experiments.
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also be mediated by the activation of the PI-3 kinase and/or
the integrin-linked kinase (Mills et al., 2003; Edwards et al.,
2005). Although in most of these studies, the NGF receptor
mediating such activity was not determined, it might be
assumed that TrkA mediates the activation of PI-3 kinase
and Akt/PKB (reviewed in Segal, 2003). Our results suggest
a novel mechanism by which NGF might inhibit GSK-3
and promote the subsequent growth of axons, mediated
only by p75NTR.
In our experimental system, NGF stimulated axonal growth
via p75NTR, and we clearly demonstrated that the inhibition of
GSK-3 promoted by NGF was mediated by p75NTR. Indeed,
the presence of the Trk inhibitor K252a did not prevent the
NGF-induced inhibition of GSK-3. Although both TrkA
and p75NTR mRNA can be found in the pyramidal cell layer
of the hippocampus (Salama-Cohen et al., 2006), it seems that
only the low-affinity receptor is involved in GSK-3 inhibi-
tion and axon elongation. Therefore, our results show that
p75NTR mediates both the inhibition of GSK-3 and axon
elongation.
From NGF/p75NTR to GSK-3 Inhibition: An Alternative
Pathway
Measurements of GSK3- activity revealed that the inhibi-
tion of PI-3 kinase by LY294002 did not prevent NGF from
inhibiting GSK-3, at least not totally (Figure 5). Because
initial studies revealed that NGF was capable of provoking
the phosphorylation of Akt/PKB, even in the presence of
LY294002, we contemplated the possibility that the levels of
phosphatidylinositol-3P might increase upon exposure to
NGF through the inhibition of a lipid phosphatase. Previous
experiments discarded SHIP I and -II phosphatases as en-
zyme targets for NGF; thus, we examined the possibility that
NGF/p75NTR regulates the activity of PTEN, thereby revers-
ing the function of PI-3 kinase by dephosphorylating phos-
phatidylinositol 3,4,5-triphosphate (Maehama and Dixon,
1998; Maehama and Dixon, 1999). Indeed, PTEN phospha-
tase has been implicated in determining neuronal polarity
and it acts upstream of GSK-3 (Jiang et al., 2005). Further-
more, PTEN overexpression in hippocampal neurons inhib-
its axon formation (Shi et al., 2003) without affecting dendrite
formation. Conversely, transfection of PTEN small interfer-
ing RNA impairs the accumulation of PTEN protein in hip-
pocampal neurons by 50% and increases the number of
axons that are produced at the expense of dendrites (Jiang et
al., 2005). The phosphorylation status of PTEN exerts a
strong influence on its regulation. Not only is it involved in
protein stabilization but also it controls the subcellular loca-
tion of PTEN and/or its association with regulatory mole-
cules (Vazquez et al., 2001; Valiente et al., 2005). Phosphor-
ylation of the PTEN tail suppresses the activity of PTEN by
interfering with electrostatic membrane binding of PTEN,
thereby controlling its recruitment into the PTEN-associated
complex (Vazquez et al., 2001).
Our results are consistent with the phosphorylation of
PTEN at Ser380 being associated with its inactivation. On
the one hand, NGF/p75NTR promotes PTEN phosphoryla-
tion, while on the other hand, the pharmacological inhibi-
tion of PTEN produces the same effect as NGF application,
namely, phosphorylation (activation) of Akt/PKB and phos-
phorylation (inhibition) of GSK-3. Furthermore, a decrease
in the phosphorylation of either Akt/PKB or GSK-3 is to a
large extent reverted in a similar manner either by inhibiting
PTEN activity with bpV(pic) or by exposing the neurons to
NGF. Therefore, our data indicate that in the pathway used
by NGF/p75NTR to activate Akt/PKB and to inhibit GSK-3,
PTEN phosphatase lies upstream of these kinases.
NGF/p75NTR Stimulates CK2 Activity
We also investigated the pathway by which NGF phosphor-
ylates PTEN phosphatase via p75NTR. One kinase known to
phosphorylate PTEN is the protein kinase CK2 (Torres and
Pulido, 2001). The depletion of CK2 in neuroblastoma cells
with antisense oligodeoxyribonucleotides blocks neurito-
genesis. This effect is accompanied by the site-specific de-
phosphorylation of microtubule-associated protein MAP1B
in parallel with the release of MAP1B from microtubules. It
has therefore been proposed that phosphorylation by CK2
may be required for correct MAP1B function in promoting
the assembly of the microtubules that constitute the cy-
toskeletal scaffolding of growing axon-like neurites (Ulloa et
al., 1993). Furthermore, it has been reported that the activa-
tion of CK2 by NGF in PC12 cells parallels neurite extension
(Kleijn et al., 1998). For the first time, we show here that NGF
largely stimulates CK2 activity in cultured hippocampal
neurons, an effect that seems to be specific because it was
completely reversed by DMAT, a specific CK2 inhibitor.
Moreover, the activation of CK2 by NGF seems to be medi-
ated by p75NTR, in accordance with other results. Interest-
ingly, the pharmacological inhibition of CK2 also prevented
the NGF-stimulated phosphorylation of both PTEN and
GSK-3.
Figure 9. Diagram depicting the mechanism by which NGF may
inhibit GSK-3 and promote axon growth. The binding of NGF to
p75 activate CK2 via an unknown process. Activated CK2 phos-
phorylates PTEN phosphatase, thus rendering it inactive and un-
able to hydrolyze PI3P. A high concentration of this secondary
messenger phosphorylates and activates Akt/PKB, which phos-
phorylates and inhibits GSK-3. The better known pathway to
increase PI(3)P concentrations consists of stimulating its synthesis
by activating PI-3 kinase. Such activation is carried out by ligand
activated protein kinase receptors such Trks, although it is unclear
whether NGF uses this pathway in hippocampal neurons.
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Together, these results reveal a novel pathway by which
NGF activates Akt/PKB, which by inhibiting GSK-3 activ-
ity, primes axon elongation. Via p75NTR, NGF activates CK2,
which in turn phosphorylates and inhibits PTEN phospha-
tase. This inhibition results in an increase in PI(3)P levels,
which stimulates Akt/PKB that subsequently phosphory-
lates and inhibits GSK-3, a necessary step for axon growth.
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